Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $190.1 million.

  • Tonix Pharmaceuticals Holding's Cash & Equivalents rose 573.17% to $190.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.1 million, marking a year-over-year increase of 573.17%. This contributed to the annual value of $98.8 million for FY2024, which is 295.93% up from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Cash & Equivalents stood at $190.1 million, which was up 51.64% from $125.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Cash & Equivalents ranged from a high of $190.1 million in Q3 2025 and a low of $4.2 million during Q2 2024.
  • Moreover, its 3-year median value for Cash & Equivalents was $28.2 million (2024), whereas its average is $65.0 million.
  • Per our database at Business Quant, Tonix Pharmaceuticals Holding's Cash & Equivalents tumbled by 90.21% in 2024 and then spiked by 2,915.66% in 2025.
  • Tonix Pharmaceuticals Holding's Cash & Equivalents (Quarterly) stood at $24.9 million in 2023, then surged by 295.93% to $98.8 million in 2024, then spiked by 573.17% to $190.1 million in 2025.
  • Its last three reported values are $190.1 million in Q3 2025, $125.3 million for Q2 2025, and $131.7 million during Q1 2025.